Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

